Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes.
about
Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional studyEctopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventionsReversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncouplerNon-alcoholic fatty liver disease: what the clinician needs to know.Apolipoprotein C3 gene variants in nonalcoholic fatty liver diseaseAntidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetesMolecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunctionTreatment of non-alcoholic fatty liver diseaseMetabolic Inflammation-Differential Modulation by Dietary ConstituentsA Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLDCurrent Management of NAFLDMedical nutrition therapy in non-alcoholic fatty liver disease--a review of literatureWeight loss in obese adults 65years and older: a review of the controversyCross-talk between the thyroid and liver: a new target for nonalcoholic fatty liver disease treatmentType 2 diabetes: etiology and reversibilityTargeting Lifestyle Behavior Change in Adults with NAFLD During a 20-min Consultation: Summary of the Dietary and Exercise LiteratureThe Flexibility of Ectopic LipidsAssociation of liver enzymes and computed tomography markers of liver steatosis with familial longevityMagnetic Resonance Imaging of Changes in Abdominal Compartments in Obese Diabetics during a Low-Calorie Weight-Loss ProgramInhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver diseaseShort-Term Hypocaloric High-Fiber and High-Protein Diet Improves Hepatic Steatosis Assessed by Controlled Attenuation ParameterMechanisms for insulin resistance: common threads and missing linksHigher liver fat content among Japanese in Japan compared with non-Hispanic whites in the United States.Magnetic resonance spectroscopy studies of human metabolism.Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetesStandardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement methodSerial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a 1 H MRS studyPhysical activity intensity and type 2 diabetes risk in overweight youth: a randomized trial.Comparative MR study of hepatic fat quantification using single-voxel proton spectroscopy, two-point dixon and three-point IDEAL.Interethnic differences in muscle, liver and abdominal fat partitioning in obese adolescents.Exercise training with dietary counselling increases mitochondrial chaperone expression in middle-aged subjects with impaired glucose toleranceNonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T.Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis.AMPK beta1 deletion reduces appetite, preventing obesity and hepatic insulin resistance.Lifestyle intervention involving calorie restriction with or without aerobic exercise training improves liver fat in adults with visceral adiposityViewpoints on the way to a consensus session: where does insulin resistance start? The liver.Effects of Low-Molecular-Weight Fucoidan and High Stability Fucoxanthin on Glucose Homeostasis, Lipid Metabolism, and Liver Function in a Mouse Model of Type II Diabetes.Metabolic changes following a 1-year diet and exercise intervention in patients with type 2 diabetesDistinct metabolic effects following short-term exposure of different high-fat diets in male and female miceWeight loss reduces liver fat and improves hepatic and skeletal muscle insulin sensitivity in obese adolescents.
P2860
Q21135215-382A08D8-1989-414E-AC63-E46E77AD5256Q21285128-509A1207-DAFA-4048-BF22-B03ABE7E5029Q24562080-F83CE0FD-DD05-4F64-AACC-F7570DCCFA3BQ24563068-00EA63DF-6711-4CE7-B800-3F22BC06C075Q24611284-A9D12EE3-9E90-439A-826A-4DFC22C41C3CQ24629052-C42F6537-1455-402E-9EB0-83EBDC79AE5CQ24632414-A7AA930C-B563-4AC9-953B-3D6DE330BE4DQ24655572-7722FE55-C4A5-4DB7-9BFB-768631629688Q26748868-CAE059FD-B162-425D-942F-20FA93CFFCFCQ26752487-DFDADC73-4DA6-48A5-9D91-6EF8B882F2F4Q26752729-5E25F124-40A5-4F4F-AE2A-ECDE0AA8E495Q26782452-F5F01D0B-6D0F-40B2-BCB6-9C1B4ED6558DQ27008343-BB75C54F-DDDB-4FD4-B3A6-A386BE0EE6B7Q27011338-D5460228-E3D6-4292-B26F-C0EA897D1743Q27016644-05DF9D60-0745-4945-A88A-E4F5055E68B2Q28075794-282E4159-EB47-46C8-86A3-88FFCF8D515AQ28076063-53375739-7DC5-4E8D-B3BE-20A2DB9567A8Q28540897-FA041EB3-F827-4DBC-B748-0829271AAAA4Q28551574-7F81CD60-17C5-4FC7-89E7-B20A1EBAFDBAQ28571421-D0D5C506-4AEF-46D0-AC84-1B82034CDB13Q28831365-CF7CE35C-F37E-4041-8C3C-51444A63C5CDQ29620447-27F91F66-85A4-462E-9C20-07CDB76DAB2CQ30435348-41A5D5C3-8E9A-486B-B375-F0FD9970EC57Q30467992-EBE18ADF-A944-4ACA-AAE8-82522FB74FC2Q30496725-CDC7E8E9-FB67-4382-B679-BE02989B9EA3Q30504580-63CF8426-5C27-49C2-84F3-A98A0AADB813Q30563967-B8694D02-D5CC-4DB7-9797-0B50AE2ABA34Q31029217-8B9A9C33-5679-4656-9A76-EFFC37DAC045Q31147984-A8D3CB6D-A439-4D57-9235-41BB602111FFQ33288964-EE81FE10-3E76-4E5F-820E-07AE6D94AF58Q33326031-27B2FED6-C3C1-4187-850D-2D9CAC55FBC6Q33409801-7450074D-7801-45CE-A817-BCAB851D9A76Q33563333-7360C54B-A9A2-4C13-BB12-200949805E06Q33581151-F98A313D-8CDC-4B2F-B377-B29B02A45B05Q33594330-675B0E31-7578-466C-9448-B2EABD8A1F98Q33610786-8674BB83-34F0-4E4F-9DD5-C9A7A0C87D84Q33612248-6D7876D4-DE44-4AFB-8B49-B4C5EC75E5EFQ33688563-4242CA85-3CB2-4A4E-B012-6AC6539C3C34Q33709596-CD1AAE58-2811-4837-A5A8-7A2237386A8EQ33709792-91771C53-DAAD-4A57-B5AC-0CA2F6CAF234
P2860
Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Reversal of nonalcoholic hepat ...... patients with type 2 diabetes.
@ast
Reversal of nonalcoholic hepat ...... patients with type 2 diabetes.
@en
Reversal of nonalcoholic hepat ...... patients with type 2 diabetes.
@nl
type
label
Reversal of nonalcoholic hepat ...... patients with type 2 diabetes.
@ast
Reversal of nonalcoholic hepat ...... patients with type 2 diabetes.
@en
Reversal of nonalcoholic hepat ...... patients with type 2 diabetes.
@nl
prefLabel
Reversal of nonalcoholic hepat ...... patients with type 2 diabetes.
@ast
Reversal of nonalcoholic hepat ...... patients with type 2 diabetes.
@en
Reversal of nonalcoholic hepat ...... patients with type 2 diabetes.
@nl
P2093
P2860
P921
P1433
P1476
Reversal of nonalcoholic hepat ...... patients with type 2 diabetes.
@en
P2093
Douglas Befroy
Michael Lehrke
Rosa E Hendler
Sylvie Dufour
P2860
P304
P356
10.2337/DIABETES.54.3.603
P407
P577
2005-03-01T00:00:00Z